Journals By Industry - Generic Drugs

An independent watchdog group has asked the Food and Drug Administration to disregard a safety panel's recommendation to keep the popular birth control drugs Yaz and Yasmin on the market, citing evidence that...

NovaDel Pharma, Inc., a specialty pharmaceutical company, has terminated license agreement with Talon Therapeutics, Inc. (formerly Hana Biosciences, Inc. ) and Par Pharmaceutical Companies, Inc., for Zensana. Talon is a biopharmaceutical company, while...

The Medicines Company (MDCO) has settled the lawsuits filed in the US district court for the district of Delaware relating to the Abbreviated New Drug Application (ANDA) filed by APP Pharmaceuticals, LLC (APP)...

NovaDel Pharma, Inc., a specialty pharmaceutical company, has terminated its license agreements with Talon Therapeutics, Inc. (formerly Hana Biosciences, Inc. ) and Par Pharmaceutical Companies, Inc., for Zensana. Talon is a biopharmaceutical company,...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/6a233b/world_generic_mark) has announced the addition of the "World Generic Markets" subscription to their offering. World Generic Markets is the business publication designed to keep executives and industry analysts...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/a40950/market_and_product) has announced the addition of the "Market and Product Forecasts: Antidyslipidemics - Set for the impact of generic Lipitor" report to their offering. The industry is bracing...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/2c0db2/market_and_product) has announced the addition of the "Market and Product Forecasts: Top 20 Oncology Therapy Brands - The value of the top 20 decreases as the oncology market...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/57b733/market_and_product) has announced the addition of the "Market and Product Forecasts: Depression - Agomelatine failure creates US market opportunity" report to their offering. New product launches across the...

JERUSALEM -- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will release its fourth quarter and full year 2011 financial results on Wednesday, February 15, 2012. Teva will host a conference...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/454d3a/product_profiles) has announced the addition of the "Product Profiles: Marketed Antibacterials - Increasing genericization and fragmentation shape a crowded market" report to their offering. In the last two...

HALLE, Germany -- Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply agreement with Actavis, one of the...

EWING, N.J. -- Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has licensed exclusively its Oxybutynin Gel 3% to Daewoong Pharmaceuticals Co. Ltd.,for marketing in South Korea. Antares will receive undisclosed...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/1c9d50/impact_of_patent_e) has announced the addition of the "Impact of Patent Expiry on Global Generic Drugs Market - Trends, Opportunities and Challenges Post 2011 " report to their offering. Fueled...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/e774ed/market_and_product) has announced the addition of the "Market and Product Forecast: Osteoporosis - Prolia and odanacatib to restore growth in the market" report to their offering. Despite major...

-Expects Record Adjusted EBITDA in the range of $85 million to $90 million- LAKE FOREST, Ill. -- Akorn, Inc. (NASDAQ:AKRX), a niche specialty pharmaceutical company, today provided full year 2012 financial guidance. The...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/147783/successful_strateg) has announced the addition of the "Successful Strategies for Pharmaceutical Reformulation" report to their offering. This report assesses the various approaches to reformulation in the protection of...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/2458e4/myocardial_infarct) has announced the addition of GlobalData 's new report "Myocardial Infarction (MI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering. GlobalData, the industry...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/318c2f/france_pharmaceuti) has announced the addition of the "France Pharmaceuticals and Healthcare Report Q1 2012" report to their offering. Despite the government's focus on fiscal consolidation - which includes...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/c7e9f8/hong_kong_pharmace) has announced the addition of the "Hong Kong Pharmaceuticals and Healthcare Report Q1 2012" report to their offering. Hong Kong continues to be viewed as a moderately...